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Extradural ropivacaine and bupivacaine in hip surgery
A. P. W o lff , L. H asselstrom , H. E. K erkkam p a n d  M. J. G ielen
Sum m ary
We studied 126 patients undergoing elective hip 
surgery; they received 20 ml of 0.5%, 0.75%, 1.0% 
ropivacaine or 0.5% bupivacaine extradurally in a 
double-blind design. Sensory block (pinprick), 
motor block (modified Bromage scale), quality of 
analgesia and neuromuscular block were assessed 
intermittently. Heart rate and arterial pressure were 
measured at regular intervals, A total of 115 patients 
were evaluated for efficacy. Onset of analgesia, 
onset of motor block and maximum cephalad spread 
(T4) did not differ between the groups. Duration 
and quality of analgesia and motor block increased 
with the concentration of ropivacaine. Ropivacaine 
1.0% provided a longer duration of analgesia and 
motor block, more intense motor block and more 
patients with satisfactory analgesia than 0.5% 
bupivacaine. More patients treated with the higher 
concentrations of ropivacaine required treatment 
for hypotension and bradycardia. (Br. J. Anaesth. 
1995; 74: 458-460)
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Ropivacaine is an amide-type local anaesthetic agent 
with a structure similar to that of bupivacaine and 
mepivacaine. It is prepared as the pure s-enantiomer 
of l-propyl-2/36/pipecolo-xylidide. It has been 
shown in animals [1] and humans [2] that the effects 
of ropivacaine on the central nervous system and 
heart are less toxic than those of bupivacaine. 
Previous clinical studies have indicated that the 
anaesthetic properties of ropivacaine and bupi­
vacaine are similar, although ropivacaine produces 
less intense motor block [3]. The intensity of motor 
block varies with the concentration of ropivacaine 
[ 4 —6 ] .
Until now there have been no data on the clinical 
efficacy of extradural ropivacaine in patients under­
going elective hip surgery. Most of these patients are 
elderly with physiological responses that affect 
responses to extradural anaesthesia. The present 
study is a dose-finding study and was undertaken to 
establish the dose-response relationship for the 
duration of analgesia and motor blocks and to assess 
the clinical efficacy of ropivacaine when used in 
extradural anaesthesia for hip surgery in 0.5%, 
0.75% and 1.0% solutions. Bupivacaine 0.5% 
served as a control.
Methods and results
This randomized, double-blind, prospective, multi­
centre study was performed in accordance with the 
principles of the Declaration of Helsinki. It was 
approved by the Ethics Committees of all partici­
pating centres. ASA I and II patients undergoing 
elective total hip replacement or hip arthroplasty 
gave informed consent to participate. The inclusion 
criteria were age between 18 and 80 yr, weight 
between 50 and 100 kg and height at least 1.50 m. 
Patients were allocated randomly to four parallel 
treatment groups to receive either 20 ml of 0.5%, 
0.75%, 1% ropivacaine or 0.5%, bupivacaine. The 
solutions were manufactured by Astra Pain Control 
AB (Sodertalje3 Sweden).
Premedication comprised diazepam 5-15 mg 
orally. All patients had an extradural catheter 
inserted at the L2-3 or L3-4 interspace. Three 
minutes after the test dose (4 ml of the study drug) 
the main dose of 16 ml was administered in in­
cremental doses over 3 min. All assessments were 
made at 5, 10, 15, 20 and 30 min after the end of 
injection. Thereafter sensory (pinprick) and motor 
block (modified Bromage scale) were assessed at 30- 
min intervals, where possible, and then hourly until 
they disappeared. Quality of analgesia and neuro­
muscular block were assessed by the anaesthetist and 
surgeon at the end of operation as satisfactory, 
satisfactory until a specified time, unsatisfactory or 
not applicable. Heart rate, systolic and diastolic 
arterial pressures and ECG were recorded through­
out surgery. Treatment for hypotension and brady­
cardia consisted of ephedrine 5 mg and atropine 
0.5 mg i.v., repeated if necessary.
The results were analysed by analysis of covariance 
and the hypothesis of equal treatment effects in the 
three ropivacaine groups was tested against the 
hypothesis of a monotonous dose-response relation­
ship by the Mantel-Haenszel test. Pairwise com­
parisons were performed between the three ropi­
vacaine groups and the 0.5% bupivacaine group.
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Table 1 Sensory block and motor block in the four groups (mean (sd) or number). Dose-dependent for 
ropivacaine: xP  = 0.0030; 2P = 0.0014; 3P = 0.0001; 4P <  0.05; 5P = 0.0006; 6P = 0.0167; 7P = 0.0465 
* Statistically significant difference (see P  values), f  Satisfactory until a specified time
Ropivacaine
Bupivacaine
0.5 %
(n = 28)
0.5 %
(n — 29)
0.75 %
Cn = 29)
1.0%
(n =  29) P
Duration of analgesia (h)
S31 4.6 (1.5) 5.2 (1.9) 6.5 (2.4) 5.2 (2.2)
L I 2 4.5 (1.8) 5.7 (2.5) 6.9 (2.6)* 5.0 (2.7)* 0.00975
T103 3.5 (1.7) 4.5 (1.9) 5.9 (2.3)* 4.3 (1.9)* 0.01598
Regression time to T124 4.3 (1.7) 5.3 (2.2) 6.9 (2.4)* 4.8 (2.4)* 0.00381
Quality of analgesia (No.)
Satisfactory 19/29 22/29 25/29* 19/28* 0.0023
Satisfactory untilf 4/29 4/29 1/29 3/28
Frequency of motor block (No.)
Degree 1 21/28 24/29 25/29 22/28
Degree 2 7/26 13/28 21/29 14/27
Degree 3 3/25 7/28 16/28 8/27
Duration of motor block (h)
Degree l 5 3.0 (1.4) 3.1 (1.3) 4.6 (1.5)* 3.3 (1.4)* 0.00844
Degree 26 2.7 (1.2) 2.6 (1.2) 3.7 (1.4)* 2.8 (1.0)* 0.03821
Degree 37 1.7 (0.5) 2.7 (1.2) 3.4 (1.5)* 2.1 (0.9)* 0.04955
Quality of block (No.)
Satisfactory 22/29 23/29 25/29 19/28
Satisfactory untilf 0/29 3/29 1/29 3/28
P  = 0.05 was considered statistically significant. All 
data are expressed as mean (sd ) unless indicated 
otherwise.
A total of 115 out of 126 patients were evaluated 
for efficacy. Apart from an overall predominance of 
females, patient characteristics did not differ between 
the four groups. Mean age was 60-65 yr for all 
groups.
The onset times of analgesia appropriate for 
surgery (T10-S3) were largely less than 30 min and 
were not statistically different. The median cephalad 
dermatomal level of analgesia was T4 for all groups. 
Extradural 0.5 % ropivacaine and 0.5 % bupivacaine 
were indistinguishable. Increasing the concentration 
of ropivacaine gave a longer duration of anaesthesia, 
a greater degree and longer duration of motor block 
and also more patients with satisfactory analgesia. 
Ropivacaine 1.0% provided a longer duration of 
analgesia and motor block, a more intense motor 
block and more patients with satisfactory analgesia 
and neuromuscular block than 0.5 % bupivacaine.
The number of patients who required additional 
anaesthesia was highest in the 0.5 % ropivacaine and 
0.5 % bupivacaine groups (five patients each), com­
pared with two patients each in the 0.75 % and 1.0 % 
ropivacaine groups. In 11 patients analgesia was 
adequate until a specified time (table 1). In most of 
these patients pain occurred when the surgeon 
started hammering the shaft of the femur to enlarge 
it for the hip prosthesis. In some patients, this was 
also the moment when satisfactory neuromuscular 
block changed to unsatisfactory. I.v. opioids were 
effective in providing analgesia in these patients. 
The use of concomitant opioids and sedatives was 
similar in all treatment groups.
Systolic and diastolic arterial pressures decreased 
in all groups. Treatment with ephedrine or atropine 
was required more often in the 0.75 % ropivacaine
group (21 of 30 and 14 of 30 patients, respectively) 
and in the 1 % ropivacaine group (29 of 29 and 9 of 
29 patients) compared with the 0.5% ropivacaine 
group (14 of 29 and 8 of 29 patients) and the 0.5 % 
bupivacaine group (17 of 28 and 7 of 28 patients).
Adverse events were mostly of mild or moderate 
intensity and almost equally distributed between the 
groups. The most common adverse events were 
paraesthesiae in one of the legs when the extradural 
catheter was inserted (14 patients) and nausea (10 
patients). All patients recovered without sequelae.
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Comment
The concentration dependent efficacy of ropivacaine 
noted in this study is in agreement with results 
reported elsewhere [3 ,4r-6]. However, this is the first 
study to test ropivacaine in a large patient group with 
a mean age greater than 60 yr undergoing hip 
surgery. In our study 1.0% ropivacaine provided 
satisfactory anaesthesia most often without unac­
ceptable side effects. The high concentration is 
responsible for the superior clinical efficacy; the use 
of this concentration is feasible because of the relative 
low toxicity of ropivacaine [1,2]. Taking into 
consideration the high median cephalad level of 
analgesia (T4) and the frequent requirement for 
vasopressors and anticholinergics, a smaller volume 
than 20 ml would probably result in adequate 
analgesia and less hypotension and bradycardia. 
Further studies are needed to evaluate volume- 
concentration relationships in older patients under­
going hip surgery in order to define the optimum 
dose.
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